- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004375
Ultraviolet Light Therapy for Systemic Lupus Erythematosus
OBJECTIVES:
I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE:
Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112-2822
- Recruiting
- General Clinical Research Center and Charity Hospital (University of Louisiana)
-
Contact:
- Hugh McGrath, Jr.
- Phone Number: 504-568-4630
- Email: hmcgra@lsuhsc.edu
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Alton Ochsner Medical Foundation Hospital
-
Contact:
- Jawed Alam
- Phone Number: 504-842-3314
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls
--Prior/Concurrent Therapy--
No requirement for tetracycline or other photosensitizing drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Investigators
- Study Chair: Hugh McGrath, Jr., Louisiana State University Health Sciences Center in New Orleans
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCRR-M01RR05096-0002
- LSUMC-1765
- LSUMC-910067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on ultraviolet A-1 light treatment
-
Henry Ford Health SystemTerminatedGeneralized VitiligoUnited States
-
Nicolas HunzelmannUniversity Hospital TuebingenTerminatedSystemic Sclerosis | Systemic SclerodermaGermany
-
Bispebjerg HospitalCompleted
-
University of MichiganArchimedes Innovations, PbcActive, not recruitingHealthy VolunteersUnited States
-
Wake Forest UniversityCompleted
-
Ultraviolet InterventionsUniversity of MarylandWithdrawnCatheter-Related InfectionsUnited States
-
University of EdinburghUniversity of Copenhagen; University of Oxford; University of Bristol; University... and other collaboratorsCompletedA Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural AsiaPesticide PoisoningSri Lanka
-
Avita MedicalTerminated
-
Karolinska University HospitalCompletedAML | ALL | Acute GVHD | Tumor ImmunitySweden
-
Cytokind, Inc.Baylor College of Medicine; Louisiana State University Health Sciences Center... and other collaboratorsCompletedAutoimmune Diseases | Covid19 | Corona Virus Infection | Coagulation Disorder, BloodUnited States